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Minutes of the Meeting 
 
The Department of Health and Human Services (HHS) and the Centers for Disease Control and 
Prevention (CDC) National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention 
(NCHHSTP) Division of Tuberculosis Elimination (DTBE) convened a meeting of the Advisory 
Council for the Elimination of Tuberculosis (ACET).  The proceedings were held on March 3-4, 







Dr. Hazel Dean, Deputy Director of NCHHSTP and Designated Federal Official of ACET, called 
the meeting to order at 8:34 a.m. on March 3, 2009.  She welcomed the attendees to the 
proceedings and particularly recognized the guest presenters and members of the public. 
  
Dr. Dean announced that ACET meetings are open to the public and all comments made during 
the proceedings are a matter of public record.  She emphasized that ACET members should be 
mindful of potential conflicts of interest identified by the CDC Committee Management Office 
and recuse themselves from participating in discussions or voting on issues in which they have 
a real or perceived conflict. 
 
Dr. Dean informed the members that the ACET charter is currently undergoing the final approval 
process at HHS.  The ACET charter would be signed and published in the Federal Register on 
March 15, 2009. 
 
Dr. Michael Fleenor, Chair of ACET, joined Dr. Dean in welcoming the attendees to the meeting 












Dr. Kevin Fenton covered the following areas in his update.  Dr. Richard Besser was appointed 
as the acting CDC Director.  He began his career at CDC in 1991 as an Epidemic Intelligence 
Service Officer and previously served as the Director of the Coordinating Office for Terrorism 
Preparedness and Emergence Response.  Dr. Besser’s background also includes work in the 
CDC National Center for Infectious Diseases, HIV activities, and pediatric TB control at the 
county level.  Dr. Fenton would meet with Dr. Besser later in the day to brief him on 
NCHHSTP’s key projects and activities. 
 
Dr. Besser appointed three Interim Deputy Directors:  Dr. Anne Schuchat, Interim Deputy 
Director for Science and Program; Mr. William Nichols, Interim Deputy Director for Management 
and Budget; and Mr. Donald Shriber, Interim Deputy Director for Policy, Legislation and 
Communication. 
 
Dr. Besser formed a team to evaluate and provide information on the impact of CDC’s various 
organizational changes over the past six years.  The team is also charged with formulating 
options for the incoming permanent Director of CDC.  Dr. Steve Thacker, Director of the Office 
of Workforce and Career Development, is leading the evaluation of CDC’s reorganization.  The 
team expects to produce a report with recommendations in mid-April 2009. 
 
On February 17, 2009, President Obama signed the American Recovery and Reinvestment Act 
of 2009, commonly known as the economic stimulus package (ESP).  Of $1 billion that will be 
available for prevention and wellness under the ESP, $300 million will be appropriated directly 
to CDC for immunization of underinsured populations under the 317 Program; $650 million will 
be appropriated to HHS/ CDC for community-based prevention and wellness strategies; and 
$50 million will be appropriated to HHS for healthcare-associated infections (HAIs). 
 
Over the past month, CDC has been identifying key projects and developing bold funding 
proposals to meet the objectives and two major priorities of the ESP:  create jobs and improve 
health impact.  However, HHS also encouraged CDC leadership to determine projects that 
could be considered as part of a larger and longer-term strategy for healthcare reform in the 
United States. 
 
At the National Center level, Dr. Kathleen McDavid Harrison was appointed as the new 
Associate Director for Health Disparities; Mr. Gustavo Aquino was appointed as the Associate 
Director for Program Integration; and Dr. Jonathan Mermin was appointed as the Director of the 
Division of HIV/AIDS Prevention (DHAP) and will assume this position in July 2009. 
 
In terms of the FY’09 NCHHSTP domestic budget, the $1 billion Conference Bill funding level 
provided $4.2 million above the FY’08 enacted budget and $6.4 million above the FY’09 
President’s budget.  In the Conference Bill, the $143.9 million appropriation for TB prevention 
was $3.5 million above the FY’08 enacted budget; the $691.9 million appropriation for domestic 
HIV/AIDS prevention and research was level with the FY’09 enacted budget; the $18.3 million 
appropriation for viral hepatitis prevention was $0.7 million above the FY’08 enacted budget; 
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and the $152.3 million appropriation for STD prevention was level with the FY’08 enacted 
budget. 
 
The outline of the President’s 2010 budget was released on February 26, 2009 and will provide 
$76.8 billion to HHS.  Specific dollar amounts that will be appropriated to individual HHS 
agencies and other details of the President’s 2010 budget are not known at this time.  However, 
language in the President’s 2010 budget calls for increased resources to detect, prevent and 
treat HIV/AIDS domestically, particularly in underserved populations. 
 
NCHHSTP convened a Social Determinants of Health (SDH) Consultation on December 9-10, 
2008 in Atlanta, Georgia to identify short- and long-term priorities for addressing SDH in HIV, 
STD, TB and hepatitis prevention.  The groundbreaking consultation represented the first time 
that CDC held an event to examine the relationship between SDH and infectious diseases.  A 
presentation on the SDH Consultation would be made during the ACET meeting. 
 
Dr. Fenton provided additional details on CDC’s recent activities with regard to the ESP in 
response to specific questions posed by the ACET members.  CDC submitted a diverse group 
of proposals to HHS to compete for ESP funding in the area of workforce development.  DTBE 
and the Division of STD Prevention submitted a proposal that focused on enhancing the 
external CDC workforce, including public health advisors and apprentice programs, in state and 
local health departments.  The NCHHSTP Office of Health Disparities submitted a proposal to 
strengthen the internal CDC workforce by using SDH to address the prevention portfolio and 
strategies. 
 
The Office of Workforce and Career Development is coordinating the submission of workforce 
proposals for CDC to compete for ESP funding in three categories:  strengthening CDC’s Public 
Health Apprenticeship Development Programs, investing in the public health workforce at state 
and local levels, and enhancing core capacities and training of public health workers for the 21st 
century. 
 
NCHHSTP and the National Center for Chronic Disease Prevention and Health Promotion 
(NCCDPHP) are evaluating a model in which community health workers were used to enhance 
HIV prevention in several Southern states.  CDC is assessing this model as an opportunity to 
expand training of professional public health workers and also to support President Obama’s 
vision of deeper and wider engagement of public health activities within communities. 
 
Dr. Fenton emphasized that because most of the prevention and wellness funds under the ESP 
are earmarked for chronic disease prevention, NCHHSTP was placed in a weaker position of 
competing for ESP dollars to address infectious diseases.  However, NCHHSTP made a strong 
case to demonstrate HIV and viral hepatitis as chronic medical conditions that require a shift in 
the traditional framework of prevention activities from an acute infectious disease focus to a 
chronic disease management focus. 
 
NCHHSTP also submitted ESP proposals for TB and STD prevention, surveillance and control 
in the United States as part of the long-term strategic planning activity for healthcare reform.  
Although NCHHSTP’s strongest ESP proposals are in the areas of HAIs, workforce issues and 
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health information technology, close collaboration with NCCDPHP will continue to clearly define 
“chronic diseases” and develop strategies to integrate infectious diseases into the chronic 
disease management framework. 
 
CDC also submitted proposals to HHS to compete for other sources of ESP funding, including 
comparative effectiveness research, health information technology to strengthen and accelerate 
the implementation of electronic health record systems across the United States, and 
modernization of surveillance and strategic information activities. 
 
In terms of new leadership, all of HHS’s major agencies currently have interim directors with the 
exception of the Health Resources and Services Administration (HRSA).  With the recent 
nomination of Governor Kathleen Sebelius as the new HHS Secretary, however, permanent 






Dr. Philip LoBue, Associate Director for Science of DTBE, presented the update on behalf of Dr. 
Kenneth Castro, Director of DTBE, who was unable to attend the meeting.  DTBE recently 
launched its annual planning process on February 24, 2009 with DTBE senior staff to develop 
three to five overarching flagship projects that will be conducted over the next three to five 
years.  The projects will be designed to have a meaningful impact on TB elimination.  DTBE will 
solicit input from ACET and other partners after the planning process is sufficiently mature. 
 
The Federal TB Task Force “Action Plan to Combat Extensively Drug-Resistant Tuberculosis” 
(XDR-TB) was published in the February 13, 2009 edition of the Morbidity and Mortality Weekly 
Report (MMWR).  The Action Plan addresses nine domestic and international response areas 
for XDR-TB:  diagnostic laboratory; surveillance, epidemiology and outbreak investigation, 
infection control; clinical and programmatic interventions; ethical and legal issues; 
communication and education; research; partnerships; and cost analysis.  The Action Plan was 
distributed to ACET for review. 
 
DTBE submitted five proposals to the CDC Coordinating Center for Infectious Diseases (CCID) 
to compete for ESP funding: 
 
1. A $5 million proposal to expand implementation of opt-out HIV testing of TB patients, 
suspects and contacts. 
2. A $2.4 million proposal to improve planning for program collaboration and service 
integration (PCSI) of TB, HIV, syphilis and hepatitis C virus (HCV). 
3. A $6 million proposal to evaluate comparative effectiveness studies of interferon gamma 
release assays (IGRAs) and tuberculin skin testing (TST) for latent TB infection (LTBI) 
diagnosis. 
4. A $3.6 million proposal to conduct a prospective evaluation of contacts exposed to 
infectious TB patients, compare treatment regimens and establish a DNA repository for 
future genetic testing. 
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5. A $15 million proposal to expand new TB screening technologies by broadly 
implementing IGRA, nucleic acid amplification testing (NAAT) and molecular drug 
susceptibility testing (DST). 
 
DTBE released online and printed versions of the 2007 Annual Surveillance Report in October 
and December 2008, respectively.  DTBE plans to publish 2008 preliminary surveillance data in 
the MMWR no later than March 20, 2009 before World TB Day.  DTBE released the revised 
report of verified case of TB (RVCT) form in January 2009 with instructions and will soon 
develop and distribute self-study modules in both print and electronic formats.  Revised RVCT 
training courses were offered to the Pacific Island TB Controllers in Hawaii and five other 
courses will be held in Atlanta in the spring of 2009.  DTBE will offer additional courses on the 
revised RVCT form as needed. 
 
DTBE is upgrading its electronic TB reporting system.  An upgrade with the revised RVCT form 
was deployed in December 2008 to 16 states that are currently using the TB program area 
module (PAM) in the National Electronic Disease Surveillance System (NEDSS).  At this time, 
six states are in production with the TB PAM.  The remaining ten states with the NEDSS base 
system will be in production with the TB PAM by the end of the first quarter of 2009.  TB 
messages were successfully sent and received during testing of the TB PAM.  States that do 
not use NEDSS will be provided with a web-based upgrade of the Tuberculosis Information 
Management System.  Beta testing of the electronic RVCT is underway in Arizona and New 
Jersey.  DTBE will offer webinar training and online support for this initiative. 
 
DTBE is continuing its involvement in two outbreak investigations.  Of 60 pediatric contacts 
identified in a TB investigation in Chuuk, Micronesia, an additional multidrug-resistant TB (MDR-
TB) death was reported and five additional cases with suspect MDR-TB disease were identified 
in November 2008-January 2009.  An article on this investigation and a surveillance report will 
be published in the MMWR for World TB Day.  DTBE conducted a contact investigation in the 
District of Columbia, Maryland and Virginia in November-December 2008.  A medical transport 
driver with TB was the potential source to 762 passengers with chronic medical conditions, but 
no evidence of transmission was detected.  DTBE will publish the results of this contact 
investigation in the MMWR. 
 
DTBE is currently re-competing the TB Epidemiologic Studies Consortium (TBESC).  The “new” 
TBESC will have a new research focus and new criteria for selecting sites.  The TBESC 
Strategic Planning Workgroup held its second meeting in January 2008 to discuss and rank six 
possible research interventions.  The workgroup selected three interventions for further 
development and consideration and will convene its next meeting in October 2009. 
 
The TBESC 14th Semiannual Meeting was held in February 2009 with ~100 participants.  The 
scientific sessions focused on (1) an evaluation of immunogenetic and immunologic markers for 
susceptibility to M. tuberculosis (M.tb) infection and progression to TB disease; (2) the 
prevalence of TB and LTBI infection among visa applicants in Mexico, the Philippines and 
Vietnam; and (3) the use of QuantiFERON®-Gold (QFT-Gold) in immigrant and refugee children 
upon arrival in the United States.  The TBESC 15th Semiannual Meeting will be held in Boston 
on July 22-23, 2009. 
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DTBE is also re-competing the TB Trials Consortium (TBTC) to strike a better balance between 
high-burden international and domestic sites.  DTBE held a pre-solicitation conference in 
November 2008 and recently released the request for proposals with a deadline of May 13, 
2009 to submit proposals for the TBTC re-competition. 
 
TBTC Study 26 is an evaluation of three months of once-weekly isoniazid (INH) and rifapentine 
for LTBI.  TBTC is conducting the study in collaboration with the AIDS Clinical Trials Group and 
the International Maternal-Pediatric-Adolescent AIDS Clinical Trials Group to increase the 
number of HIV-infected patients enrolled in the study.  TBTC Study 29 is an evaluation of high-
dose rifamycin therapy.  To date, 38 patients have been enrolled.  TBTC Study 30 is an 
evaluation of linezolid in MDR-TB patients and is scheduled to begin in April 2009 in Durban, 
South Africa. 
 
DTBE is continuing its efforts on the National TB Indicators Project (NTIP).  This system utilizes 
existing reportable data; standardizes measurements for tracking progress toward objectives; 
and can be used at national, state and local levels.  NTIP will guide program evaluation efforts 
and reinforce national priorities for TB programs.  DTBE will roll out the NTIP pilot to TB 
programs later in March 2009. 
 
DTBE changed the name of the Evaluation Workgroup to the TB Program Evaluation Network 
(PEN) to better organize and more strongly reflect the activities of this initiative.  TB PEN goals 
were designed for state and local programs to build capacity to conduct ongoing monitoring and 
evaluation; engage in program monitoring and evaluation; provide feedback; share lessons 
learned from evaluations; and use evaluation findings to make systemic changes. 
 
DTBE will hold the annual meeting of the TB Education and Training Network (TBETN) on July 
28-30, 2009 in Atlanta, Georgia.  The meeting is entitled TB Education and Training: Recipes for 
Success and will include a joint meeting with the TB PEN to provide focal points for training and 
education. 
 
World TB Day will be held on March 24, 2009.  The communication and education resources for 
this event include an updated CDC web page with links to resources; a graphical web button, 
the CDC.gov feature, and data and statistics on the CDC and DTBE web sites; and posters, an 
e-card, and descriptions of events occurring within CDC and across the country. 
 
The ACET members made a number of comments and suggestions for DTBE to consider in 
refining its ongoing projects and activities. 
 
 DTBE should offer more cost-effective mechanisms to provide training on the TB PAM, 
such as online webinars, teleconferences or regional training sessions.  Limited 
resources have increased the difficulty for TB controllers to attend training at CDC in 
Atlanta. 
 DTBE should ensure that NTIP and TB PEN have a strong linkage and feedback 
mechanism.  These initiatives are designed for different purposes, but have the capacity 
to share lessons learned, data from cohort reviews and evaluation methods. 
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 DTBE should capitalize on upcoming opportunities with ESP funding to enhance 
implementation of electronic medical record systems.  TB programs are challenged by 
entering patient records into the current system and then inputting the same data into 
NEDSS.  DTBE would have better compliance with data reporting if portals are 
developed for TB programs to upload Health Level 7 compatible data.  This mechanism 
also would allow TB programs to analyze state and local data and make relevant 
programmatic adjustments. 
 DTBE should use NTIP as an opportunity to explore and incorporate innovations or best 
practices into TB programs.  DTBE also should design a rigorous quality improvement 
model for NTIP to help build an iterative learning process in the operation of TB 
programs. 
 
In response to one of ACET’s suggestions, Dr. Fenton confirmed that if CDC is successful in 
leveraging ESP funds, close collaborations would be established with colleagues across the 






Dr. Kashef Ijaz, Chief of the DTBE Field Services and Elimination Branch, explained that 
13,929 TB cases were reported in the United States in 2007 for an overall TB case rate of 
4.4/100,000.  In response to the changing TB epidemiology, DTBE and its partners developed a 
funding formula to more equitably distribute TB dollars. 
 
In 2005, 20% of the total amount of funds allocated to state and local TB control programs were 
redistributed.  In 2008, the 20% redistribution amount was increased to 35%.  In 2010, the 35% 
redistribution amount will be increased to 45%.  In 2013, the 45% redistribution amount will be 
increased to 60%.  The ultimate goal of the TB funding formula is to redistribute and align all 
funds with data-driven epidemiologic needs and TB elimination objectives of TB control 
programs in the United States. 
 
In 2008, the 35% redistribution formula was weighted based on data reported to CDC in 2001-
2005 for specific occurrences of TB cases in various subpopulations.  The formula relied on a 
five-year average of 40% of incident cases, 15% of U.S.-born minorities, 15% of foreign-born 
populations (FBPs), 10% of Class A/B1/B2 TB, 5% of HIV co-infection, 5% of MDR-TB, 5% of 
substance abuse, and 5% of the homeless population. 
 
DTBE and the National Tuberculosis Controllers Association (NTCA) formed the FY2010 
Formula Workgroup to achieve three major objectives.  Existing formulas for the prevention, 
control and laboratory components would be reviewed and recommendations would be made 
on any necessary revisions to the FY2010 TB cooperative agreement funding allocations.  
Criteria for direct TB cooperative agreement funding to big cities in the future would be 
assessed.  The distribution of funds to hold-harmless states that receive <$255,000 for TB 
would be evaluated.  
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DTBE thoroughly reviewed the workgroup’s recommendations and made the following decisions 
on the three objectives for the FY2010 TB formula for the prevention and control components.  
For objective 1, the funding formula, DTBE decided on a 45% redistribution formula based on 
data reported to CDC in 2004-2008 for specific occurrences of TB cases in various 
subpopulations.  DTBE decided that the formula would rely on a five-year average of 30% of 
incident cases, 35% of U.S.-born minorities and FBPs, 15% of smear- or culture-positive 
pulmonary TB, 5% of HIV co-infection, 5% of MDR-TB, 5% of substance abuse, and 5% of the 
homeless population. 
 
For objective 2, direct funding to big cities, DTBE decided to maintain the current level of 
funding to the directly funded big cities until 2013 or 2015.  DTBE’s decision was based on the 
inability to cap indirect costs; the CDC Procurement and Grants Office’s distinction between 
“continuing competitive” and “non-continuing competitive” announcements; major funding cuts 
at city and state levels; the potential of inadvertently adding new indirect costs to cities that 
currently have no indirect costs; and the need to publish the FY2010 cooperative agreement.  
DTBE will continue to collaborate with the NTCA Formula Workgroup, states and cities on the 
transition plan.  DTBE also will further explore the workgroup’s recommendation to establish a 
baseline threshold and discontinue direct funding if a big city falls below this level. 
 
For objective 3, redistribution of funding among hold-harmless states, DTBE agreed not to apply 
the FY2010 TB funding formula.  However, a base minimum funding level of $100,000 will be 
established.  States that receive less than the base minimum funding level will receive additional 
funds to be equal to the base.  States that receive >$100,000 will receive the same amount. 
 
Dr. Angela Starks is a Senior Science Fellow and Leader of the Capacity Building Activity in 
DTBE.  She explained that DTBE and the Association of Public Health Laboratories (APHL) 
formed a TB Laboratory Formula Workgroup with representation from NTCA, laboratory 
directors and supervisors in low-, moderate and high-incidence states.  DTBE thoroughly 
reviewed the workgroup’s recommendations and made the following decisions on the FY2010 
TB formula for the laboratory component. 
 
DTBE decided that the redistribution formulas for the TB laboratory and prevention/control 
components would be parallel:  55% of funds would be distributed based on historical funding 
and 45% of funds would be distributed based on workload.  Funds distributed in FY2010 would 
be based on the current formula of the number of TB cases for which the laboratory provided a 
test result for completion of surveillance reports.  DTBE decided on this approach to allow 
laboratories at least one year to collect retrospective data that will be required for elements of 
the new TB formula. 
 
DTBE decided on six elements for the TB laboratory formula in FY2011-FY2014: 
 
1. The total number of specimens [5% weight]. 
2. The number of patients for whom a TB culture was inoculated [15% weight]. 
3. The number of patients for whom a reference isolate was received by the laboratory for 
identification [15% weight]. 
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4. The number of patients for whom NAAT is performed to detect M.tb directly from a 
clinical specimen [25% weight]. 
5. The number of patients for whom DST is performed for first-line drugs [25% weight]. 
6. The formation of a laboratory system to encourage collaboration and communication 
among clinicians, TB laboratories and TB control programs [15% equal amount among 
all laboratories]. 
 
DTBE will use data provided by laboratories to determine funding amounts for each of the six 
elements.  The amounts of the individual elements will be added together to determine the 
formula-based portion of the award.  DTBE’s process of distributing TB funds for the laboratory 
component in FY2010-FY2014 is summarized below. 
 
In FY2010, the current distribution formula of 55% base funding/45% formula funding would be 
parallel to the TB prevention and control component.  In FY2011 and FY2012, the 55%/45% 
distribution would remain the same, but the six elements would be implemented with an 
incentive for laboratories that perform NAAT.  In FY2013 and FY2014, the 55%/45% distribution 
would change to 40% base funding/60% formula funding with no incentive for laboratories that 
perform NAAT. 
 
The ACET members made a number of comments and suggestions for DTBE to consider 
before implementing the TB funding formula in FY2010. 
 
 DTBE should develop a more equitable formula to distribute TB funding.  Most notably, 
Seattle-King County and other metropolitan areas with a high burden of TB cases that 
are not designated as “big cities” are not eligible for direct funding. 
 DTBE should provide TB programs with clear guidance on using social determinants to 
more effectively address the subpopulation of U.S.-born minorities/FBPs in the TB 
funding formula. 
 DTBE should make efforts to account for the duplication of subpopulations in the TB 
funding formula.  For example, one state with an incidence of 5% of HIV co-infection, 5% 
of substance abuse and 5% of the homeless population would receive funding for all 
three subpopulations.  This approach would misrepresent the total impact of TB in the 
state.  DTBE could address this issue by requiring grantees to consult with at least 50% 
of health jurisdictions in the state that cover at least 50% of the population in the state. 
 DTBE should conduct an analysis to determine whether the TB funding formula for the 
laboratory component would drive some state laboratories to engage in a regional model 






Dr. Tanya Sharpe, Deputy Director of the NCHHSTP Office of Health Disparities, announced 
that NCHHSTP convened a consultation on December 9-10, 2008 to address social 
determinants of HIV/AIDS, viral hepatitis, STD and TB.  For purposes of the consultation, 
NCHHSTP used the World Health Organization (WHO) Commission on Social Determinants of 
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Health’s published definition of SDH:  “the range of personal, social, economic and 
environmental factors that determine the health status of individuals or populations.” 
 
During the consultation, NCHHSTP made a presentation on the relative influence of the five 
categories of determinants of population health that were published in 1999:  genes and biology, 
health behaviors, medical care, total ecology, and social and societal characteristics.  The study 
demonstrated that total ecology and social/societal characteristics account for ~75% of 
determinants of population health. 
 
For purposes of the consultation, NCHHSTP used WHO’s three action steps for addressing 
SDH.  First, conditions of daily life should be improved, including circumstances in which 
persons are born, grow, live, work and age.  Second, inequitable distribution of power, money 
and resources should be tackled, including structural drivers of the conditions of daily life at 
global, national and local levels.  Third, the problem should be measured and understood; the 
impact of action should be assessed; the knowledge base should be expanded; a workforce that 
is trained in SDH should be developed; and public awareness about SDH should be raised. 
 
NCHHSTP convened the consultation to support its programmatic priority of reducing health 
disparities and develop a comprehensive approach to address health disparities that considers 
SDH.  The consultation also provided an opportunity for the participants to provide external 
input on key priorities to address social determinants of HIV/AIDS, viral hepatitis, STDs and TB 
that would be reasonable for NCHHSTP to undertake. 
 
Moreover, the consultation served as a forum for 117 stakeholders to discuss more effective 
strategies to address social determinants of NCHHSTP’s infectious diseases in four key public 
health areas:  public health policy, agency partnerships and capacity building, data systems 
(surveillance and epidemiology), and prevention research and evaluation.  The participants 
served on breakout groups for the four public health areas and made a number of key 
suggestions. 
 
The Public Heath Policy Group advised NCHHSTP to provide leadership throughout CDC and 
align efforts with those of HHS and WHO.  The group also suggested that NCHHSTP convene a 
national agenda setting meeting and partner with other federal agencies, non-governmental 
organizations, private foundations, philanthropic organizations and others with an interest in 
reducing health disparities. 
 
The Data Systems Group advised NCHHSTP to identify key data elements and measurements 
that would be needed to develop and launch a national SDH initiative.  The group also 
suggested that NCHHSTP share, link and integrate data to the extent possible to facilitate data 
analyses and provide a strong evidence base for SDH. 
 
The Agency Partnerships and Capacity Building Group advised NCHHSTP to build capacity 
among SDH partners by including language in funding opportunity announcements and 
requiring state and local grantees to collaborate with and outreach to partners at state and local 
levels.  The group also suggested that NCHHSTP launch a nationwide social marketing 
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campaign to strengthen the relationship between CDC and at-risk populations and engage a 
broader group of partners in delivering messages on infectious diseases. 
 
The Prevention Research and Evaluation Group advised NCHHSTP to reframe traditional 
individual-based strategies and broaden targeted groups on the basis of families, communities, 
systems, partnerships and organizations.  The group also suggested that NCHHSTP advance 
participatory research in which communities would be engaged from the beginning of 
conceptualizing studies to the end of finalizing projects. 
 
NCHHSTP’s next steps in the SDH initiative are summarized as follows.  A summary report will 
be distributed to all participants who attended the consultation within the next two weeks.  A 
communications plan is being created to guide, mobilize and inspire actions in SDH at federal, 
state, local and community levels.  A white paper with both short- and long-term goals is being 
developed. 
 
Both short- and long-term planning processes for SDH are underway in the NCHHSTP Office of 
Health Disparities.  A special issue on SDH and its relationship to HIV/AIDS, viral hepatitis, 
STDs and TB will be published in Public Health Reports in 2010 and NCHHSTP will make 
additional contributions to the scientific literature.  Key recommendations from the consultation 
and other SDH events will be used to inform NCHHSTP’s 2009-2015 Strategic Plan that will be 
launched in FY2009. 
 
Overall, the consultation was successful in identifying key priorities in four public health areas 
and will help to form an SDH strategy with clear goals and objectives.  The consultation 
demonstrated the commitment of CDC’s partners in addressing and broadening the 
conversation about SDH and engaging traditional and non-traditional federal and private-sector 
stakeholders that are concerned about reducing health disparities. 
 
ACET commended NCHHSTP on convening the groundbreaking SDH Consultation that cut 
across all divisions in the National Center.  The ACET members who attended this event noted 
that the consultation provided an amazing framework to begin to analyze issues related to the 
social determinants of HIV/AIDS, viral hepatitis, STDs and TB. 
 
Several ACET members made suggestions and comments for NCHHSTP to consider in its 
further development of the SDH initiative. 
 
 NCHHSTP should advance the SDH initiative to examine the role of program integration 
and social and cultural determinants of health in producing better outcomes, increasing 
employment opportunities, and using community outreach workers on a larger scale.  
These components of SDH should be incorporated into ESP activities, the FY2010 TB 
funding formula and NCHHSTP’s other ongoing projects. 
 NCHHSTP should partner with and encourage private provider groups to collect and 
report racial/ethnicity data on HIV/AIDS, viral hepatitis, STDs and TB to CDC.  
NCHHSTP also should use upcoming opportunities in the ESP to collaborate with 
private-sector companies to develop methodologies to capture and measure racial/ 
ethnic data elements in electronic medical records. 
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 NCHHSTP should reconsider using the WHO Commission on Social Determinants of 
Health’s definition of SDH.  NCHHSTP could make a strong contribution and strengthen 
the theoretical basis by developing a more meaningful definition of SDH. 
 NCHHSTP should ensure that the SDH initiative is embedded as a strong theme and 
comprehensive approach in all infectious disease projects.  With TB, for example, SDH 
should be incorporated into state and local TB programmatic activities, DTBE’s TB in 
African Americans (AAs) projects, and CDC’s updated “Recommendations for 






Dr. Drew Posey, of the DGMQ Immigrant, Refugee and Migrant Health Branch, reported on 
DGMQ’s ongoing activities related to the TB Technical Instructions (TBTIs) and Electronic 
Disease Notification (EDN) system.  In terms of the TBTIs, all immigrants and refugees who 
apply for U.S. immigration are required to undergo TB screening.  The 1991 TBTIs only relied 
on sputum smears, were inadequate to detect all applicants with TB disease, and missed 
smear-negative/culture-positive persons. 
 
To address these issues, DGMQ developed and implemented updated TBTIs in 2007 that 
required TST for applicants 2-14 years of age in areas where WHO estimated the TB rate to be 
>20/100,000.  Other requirements of the 2007 TBTIs include sputum cultures for all applicants 
suspected of having TB; DST on positive isolates; treatment according to American Thoracic 
Society (ATS)/CDC/Infectious Disease Society of America guidelines; and treatment delivered 
as directly observed therapy (DOT) throughout the entire course of therapy. 
 
FY2007 data show that populations from 18 countries, or 33% of immigrants and 40%-50% of 
refugees, are currently being screened according to the 2007 TBTIs.  The TBTIs are now being 
implemented in the Dominican Republic.  This country is the fifth largest source of immigrants to 
the United States and accounted for 17,880 arrivals in FY2007.  A private laboratory will perform 
the cultures and DST.  The panel physicians and National Tuberculosis Program will provide 
DOT to the applicants with TB. 
 
Other activities to support implementation of the 2007 TBTIs in FY2009 are described as 
follows.  China is the third largest source of immigrants to the United States and accounted for 
33,295 arrivals in FY2007.  CDC will make a site visit to China later in March 2009 to finalize 
arrangements for implementation of the 2007 TBTIs.  CDC is currently providing training to East 
African panel physicians in Kenya and will offer the same training seminar to Asian panel 
physicians in the Philippines in April 2009. 
 
ACET and NTCA will conduct an evaluation of the International Organization for Migration (IOM) 
program in August 2009 in Nepal.  This country is the site of the Bhutanese refugee 
resettlement and will account for >60,000 arrivals over the next few years.  During FY2009, 
15,000 Bhutanese refugees are expected to resettle to the United States.  In Jordan, the 
Ministry of Health will serve as the culture laboratory.  An IOM laboratory expert from Nairobi, 
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Kenya recently provided technical expertise on culture and DST to the Jordanian Ministry of 
Health at its TB laboratory. 
 
DGMQ partnered with DTBE and the Regional Training and Medical Consultation Centers 
(RTMCCs) to provide clinical intensive TB training courses to panel physicians.  In 2008, 13 
overseas panel physicians from Ghana, Ethiopia, Kenya, Nepal, Thailand, Egypt and the 
Philippines attended these courses.  The panel physicians and RTMCCs provided excellent 
feedback on the training courses. 
 
U.S. Department of State (DOS) forms are completed by overseas panel physicians and are 
being updated to incorporate changes from the 2007 TBTIs.  The forms are currently 
undergoing the DOS review process.  Implementation of the updated forms is targeted for 
October 1, 2009 in parallel to the update of the EDN system and the update of the EDN-IOM 
electronic interface for refugee medical examinations. 
 
The TBTI document also is being updated to be consistent with the new DOS forms and allow 
for incorporation of changes based on recommendations made by the TBTI Workgroup and 
evaluators who assessed the implementation of the TBTIs in the Philippines in 2008.  
Implementation of the updated TBTI document and the new DOS forms will be linked.  A draft of 
the updated document was recently distributed to the TBTI Workgroup for review and comment. 
 
Overall, the 2007 TBTIs have increased the yield and diagnosis of TB overseas.  In the 
Philippines, for example, 302 smear-negative/culture-positive cases were diagnosed in the first 
fiscal year in which the TBTIs were implemented.  The TBTIs also have provided an opportunity 
for overseas panel physicians to participate in TBESC meetings and other events. 
 
In terms of EDN, this electronic system allows information to be sent to receiving health 
departments on all refugees who arrive in the United States and all immigrants who arrive in the 
United States with a Class A or Class B TB condition.  EDN also serves as a mechanism for 
health departments to enter results of post-arrival TB evaluations.  All 50 states receive 
information electronically through EDN and all quarantine stations are linked to EDN as well.  
Since October 1, 2008, 16,648 notifications were sent through EDN.  Of 2,182 B1 notifications 
that received a TB evaluation, 402 worksheets were returned to the EDN system. 
 
DGMQ and DTBE jointly convened an EDN Summit in November 2008 with representatives 
from the NTCA EDN Workgroup and the Association of State Refugee Health Coordinators 
(ARHC).  DGMQ has taken a number of actions in response to suggestions for improvement 
and recommendations the participants proposed during the summit.  For “technical issues,” 
DGMQ developed and presented a road map for technical improvements to the NTCA EDN 
Workgroup.  For “data analysis and reporting,” DGMQ is currently developing a reporting format 
and time frame. 
 
For “communication and feedback,” DGMQ is improving its regular communications with states 
both in terms of frequency and individual contacts.  For “training and educational products,” the 
development of an EDN User’s Manual is underway.  DGMQ is working to consolidate the 
leadership of EDN and hire an EDN Manager to have overall coordination of the system.  It is 
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hoped this will better allow recommendations from the summit to be follow-ed up on and allow 
for integration of EDN with other systems.  The final report of the summit was distributed to 
ACET for review. 
 
EDN currently has a one-month backlog because DGMQ underestimated the data entry needs 
when West Coast quarantine stations began sending information to EDN in December 2008.  In 
January 2009, the Customs and Border Patrol gave a large volume of medical packets to 
quarantine personnel in key stations for persons who arrived in the United States in December 
2008.  DGMQ had no additional data entry capacity to meet this need. 
 
DGMQ is taking a number of actions to resolve the EDN backlog.  A comprehensive analysis is 
being conducted to determine the cause of the backlog and document all potential causes for 
the delays.  The analysis is focusing on quarantine station operations of sending information to 
EDN, data entry needs, and technical issues that might delay notification after data entry. 
 
Additional data entry personnel were recently hired and more permanent and temporary staff 
will be made available in preparation of the surge in refugee arrivals in the summer of 2009.  
Informatics changes are being made to reduce the time between data entry and notification.  
DGMQ will soon provide a progress report to AHRC and the NTCA EDN Workgroup on the 
status of the EDN backlog. 
 
DGMQ discussed with states the concept of not including a scanned copy of the medical packet 
with EDN notifications.  DGMQ provided a strong rationale to support this approach.  Electronic 
records are now much more accurate and the provision of a scanned copy for IOM refugees is 
redundant.  Moreover, data entry personnel spend 30% of their time scanning medical records.  
Scanning also greatly contributes to delays in notifications. 
 
Due to concerns expressed by NTCA and ARHC, a decision was made to continue to include a 
scanned copy of the medical packet with EDN notifications.  However, DGMQ will follow up with 
NTCA and ARHC to better explain procedures that make electronic records more accurate, 






Ms. Sonia Montiel is the Binational Laboratory Coordinator at CDC.  She explained that the 
Mexico Ministry of Health and CDC jointly conducted a study in 1997 to obtain data on TB drug 
resistance.  The study was published in 1998 and showed that the MDR-TB incidence was 2.4% 
for primary resistance, 22.4% for previously treated persons, 12.4% for primary resistance to 
INH, and 56% for secondary resistance. 
 
The study was limited in the following areas.  Notification was delayed; 26% of cases reported 
to the Mexico Ministry of Health were not included; 27% of specimens were not cultured by the 
national laboratory; and the data were not nationally representative because only three states 
were included.  To address these limitations, the National Tuberculosis Drug Resistance Survey 
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was initiated in February 2008 with the standardized WHO methodology of multi-stage cluster 
sampling and a formula recommended by WHO and the International Union Against 
Tuberculosis and Lung Disease (IUATLD) in 2003. 
 
The U.S. Agency for International Development is funding the study to determine the magnitude 
of pulmonary drug-resistant TB in Mexico to strengthen the National Program.  The sample 
calculation includes a TB case prevalence of 1,954 new cases, 542 cases with prior treatment, 
and 8% of lost samples.  The study population includes pulmonary TB cases identified in clinics 
and the geographic coverage is based on 2005 national surveillance data.  The total sample 
size of 2,700 specimens represents nine high-, medium- and low-incidence states, 53 
jurisdictions and 4,365 health clinics. 
 
Inclusion criteria for the study are patients <18 and >18 years of age who are new or previous 
smear-positive pulmonary TB cases.  New and previous TB cases that are currently undergoing 
TB treatment as well as smear-positive contacts of patients who meet the inclusion criteria are 
excluded from the study.  Elimination criteria include incomplete data on new or pretreated 
conditions, the exclusion of both samples and inconclusive results on both cultures. 
 
The process to collect data from study participants is outlined as follows.  Patients with 
respiratory symptoms would visit a local health facility and provide three sputum specimens.  
The local or state public health laboratory would perform smear testing.  For positive smear 
results, a risk factor survey would be administrated and a second sputum specimen would be 
collected at the patient’s home.  The samples would be sent to state and national laboratories in 
Mexico.  The best samples would be cultured at CDC and the national laboratory in Mexico. 
 
The Agar proportion method and Bactec 460 will be used to perform DST to detect M.tb with ten 
drugs.  The Mycobacterial Growth Indicator Tube (MGIT) automated method will be used for 
pyrazinamide (PZA).  Monoresistant PZA spoligotyping also will be performed to detect 
Mycobacterium bovis.  The total sample size that will be sent to CDC for proficiency testing and 
quality control is anticipated to be 612 specimens.  As of February 2, 2009, 2,451 cases or 
~91% of samples were enrolled in the study.  All specimens are expected to be collected by the 
end of March 2009. 
 
Challenges to the study include difficulties in locating patients due to persons who were 
homeless, gave wrong addresses or moved across the state or the U.S.-Mexico border.  
Changes in local or state personnel required additional training.  Samples were lost or 
improperly packaged and stored.  Delays also occurred in sending specimens to the state or 
national laboratory.  Shortages of laboratory staff resulted in delays in smear testing and 
delivery of specimens to the jurisdiction and state.  CDC has no knowledge at this time when 
the study will be published.  Although ~91% of samples have been collected, Mexico has sent 
no isolates to CDC for blind testing to date. 
 
ACET was pleased that CDC is undertaking this effort because the study will provide important 
new information on the incidence of TB drug resistance in Mexico.  Several ACET members 




ACET Meeting Minutes                                  March 3-4, 2009                                                         Page 16 
 The methodology should clearly state the purpose or objectives of the study, particularly 
the frequency of MDR-TB in Mexico.  The methodology also should describe HIV co-
infection, high-incidence states in Mexico, intravenous drug use and other risk factors for 
MDR-TB to assist clinicians in proactively treating these patients. 
 Consideration should be given to including Tamaulipas, Mexico in the study due to the 
high incidence of TB in this state.  The study most likely will underestimate the true 
incidence of TB drug resistance in Mexico due to the exclusion of Tamaulipas. 
 A history of hospitalization and incarceration of persons with TB should be analyzed in 
the study as strong factors for MDR-TB.  For example, a survey administered in Siberia 
on the potential causes of MDR-TB demonstrated that hospitalization for drug-
susceptible TB was the major factor in this setting.  The Siberian study also showed that 
institutional transmission and re-infection played a significant role in MDR-TB in this 
setting. 
 Agreements should be established with laboratories to send specimens directly from 
Mexico to the United States.  The transport of specimens from local clinics to Mexico 






Ms. Rachel Stricof is the ACET liaison to both HICPAC and the Association for Professionals in 
Infection Control and Epidemiology.  She explained that the mission of HICPAC is to protect 
patients and healthcare personnel (HCP) and also to promote safety, quality and value in 
healthcare delivery.  Similar to ACET, HICPAC also is a federal advisory committee that is 
chartered to provide guidance and recommendations to the HHS Secretary and CDC Director.  
Unlike ACET, however, HICPAC is not a legislatively mandated committee.   
 
HICPAC members are recommended by CDC and appointed by the HHS Secretary.  HICPAC’s 
14 voting members develop strategies and issue guidelines for surveillance, prevention and 
control of HAIs.  HICPAC also engages in information exchange with CDC staff and has both 
formal and informal interactions with other CDC advisory committees.  HICPAC’s liaison and ex-
officio members represent a diverse group of federal agencies and professional organizations. 
 
Many of HICPAC’s areas of focus overlap with those of ACET.  Most notably, HICPAC’s focus 
on healthcare outcomes targets the incidence of disease, disability, death and cost of care, 
while its focus on emerging antimicrobial-resistant infections includes TB and MDR-/XDR-TB as 
models.  HICPAC’s other key areas of focus include (1) prevention and control of outbreaks and 
transmission of infectious agents in healthcare settings; (2) clinical microbiology laboratory 
efficiency, accessibility and quality; (3) cost and effectiveness of prevention interventions; and 
(4) development of infection control guidelines and policies. 
 
On the one hand, several guidelines HICPAC has published over time are of interest and 
relevance to ACET’s mission and key target audience of TB control programs, such as the 1998 
Infection Control in Healthcare Personnel Guideline that will be updated in the near future, the 
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2003 Environmental Control in Healthcare Facilities Guideline, and the 2007 Isolation 
Precautions Guideline. 
 
On the other hand, a number of ACET’s previously published and upcoming guidelines are of 
interest and relevance to HICPAC’s mission and key target audience of healthcare facilities, 
such as the 2003 Adverse Event Data and Revised ATS/CDC Recommendations Against the 
Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection and the 2005 
Guideline for Preventing Transmission of Mycobacterium tuberculosis in Healthcare Settings.   
 
ACET also will update the 1996 Guideline on the Role of BCG Vaccine in the Prevention and 
Control of Tuberculosis in the United States and the 2005 Guideline for Using the 
QuantiFERON®-TB Gold Test for Detecting Mycobacterium tuberculosis Infection in the United 
States.  Moreover, ACET will issue an updated Guideline for the Use of Nucleic Acid 
Amplification Tests in the Diagnosis of Tuberculosis in 2009. 
 
HHS’s new “National Policy on Lowering HAIs” is another area that is of interest and relevance 
to both ACET and HICPAC.  Although the current incidence of HAIs in the United States is 1.7 
million and accounts for ~99,000 deaths each year, no systematic approach has been 
established to date to reduce or prevent HAIs.  However, ESP funding of $50 million will be 
allocated to states for HAI prevention activities.  In preparation of the ESP funding, HHS 
described its role in reducing HAI rates during the June 2008 HICPAC meeting.  At that time, 
HICPAC accepted HHS’s formal charge to provide subject matter expertise in helping to 






Dr. Starks described DTBE’s proposal to conduct a comprehensive assessment of available TB 
laboratory services in the United States.  At this time, 60%-70% of clinical decisions are directly 
influenced by laboratory results, including the initial diagnosis, decisions on releasing patients 
from isolation, and initiation of appropriate drug therapy.  Even if a strong clinical suspicion for 
TB exists, some clinicians will delay treatment decisions until laboratory results are available. 
 
To ensure continued progress in reaching the goal of TB elimination in the United States, a 
determined effort must be made to strengthen domestic TB laboratory capacity.  Critical steps in 
this effort are to promote timely laboratory testing and ensure strong communications among 
public and private laboratories, clinicians and TB control programs.  Moreover, jurisdictions must 
have access to high-quality TB testing and timely data reporting must occur as well. 
 
The 2009 Federal TB Task Force Plan to Combat XDR-TB and the 2002 APHL/CDC Future of 
TB Laboratory Services Report both recommended a comprehensive assessment of available 
TB laboratory services in the public and private sector in the United States.  The CDC Public 
Health Practice Program Office conducted an assessment in 1999 to determine training needs, 
but this evaluation was not comprehensive. 
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Of the national sample of mycobacteriology laboratories evaluated in 1999, 35.5% performed 
acid fast bacilli microscopy only, 46.5% performed culture without identification, 10.3% 
performed culture and identification, and 7.7% performed DST.  The 1999 assessment showed 
that TB testing required referrals among public and private laboratories with different levels of 
service.  The assessment also emphasized the need to ensure coordination between public and 
private sectors for referral services to prevent unnecessary delays. 
 
Under TBESC Task Order 6, a laboratory survey was recently administered to assess 
laboratory services in the low-incidence states of Idaho, Montana, Utah and Wyoming and 
showed the following findings.  A minimal number of laboratories in the region performed 
mycobacteriology services.  Laboratories that provided services had very low specimen 
volumes.  Most laboratories were not meeting goals for turnaround times.  In response to the 
survey results, CDC offered training to the laboratories in the region to address turnaround 
times and reporting issues. 
 
A comprehensive assessment of available TB laboratory services in the United States is still 
needed at this time because the 1999 training needs assessment and TBESC laboratory survey 
were quite focused.  These two activities also did not address three outstanding issues.  
Jurisdictions might have limited knowledge about the status of TB laboratory services in their 
respective areas.  A national picture of the current state of TB laboratory services is lacking.  
Gaps in laboratory knowledge and services need to be identified; barriers to sharing best 
practices within the laboratory community need to be overcome; and communication and 
training issues need to be addressed to develop and disseminate appropriate materials. 
 
DTBE and APHL are collaborating to conduct a number of activities to support the development 
of a comprehensive laboratory services survey instrument.  A face-to-face meeting will be 
convened with relevant subject matter experts to develop and refine the survey instrument.  A 
list of laboratories to survey will be created.  Pilot testing will be performed with a subset of 
public and private laboratories.  Approval of the survey instrument will be solicited from the 
Office of Management and Budget.  The comprehensive survey will be implemented in various 
local jurisdictions.  Data will be analyzed and quality improvement plans will be developed.  A 
report with recommendations will be written. 
 
The survey topics will focus on available services in each laboratory, test methods and volumes, 
turnaround times and reporting processes, existing referral strategies, training needs, and 
relationships between public health laboratories and TB control programs.  Survey data for 
jurisdictions will be provided to public health laboratories to increase awareness of TB services 
and provide an opportunity to take the lead in developing an integrated laboratory system for TB 
laboratories, control programs and clinicians. 
 
At the local level, potential focus areas for jurisdictions will include improved coordination for 
referral of specimens and cultures; elimination of delays in laboratory testing and reporting; 
implementation of changes in services based on data; and development of baseline data for 
quality assessment activities, such as data reporting to stakeholders.  The overarching goal of 
this effort will be to empower laboratories to use the comprehensive survey instrument to 
periodically reevaluate available laboratory services at the local level. 
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At the national level, DTBE will develop relevant training materials such as webinars, 
conference sessions and National Laboratory Training Network classes.  These data also could 
be useful to DTBE to guide decision-making for funding, projects, future research questions and 
the establishment of new “TB Testing Centers of Excellence.”  
 
Dr. Starks concluded her overview by requesting ACET’s feedback in the following areas:  
general comments on DTBE’s proposal to conduct the comprehensive assessment of available 
TB laboratory services in the United States; suggestions on the design of the survey instrument; 
and a formal endorsement, response or recommendations to the comprehensive laboratory 
services survey.  Because DTBE has not yet secured funding for this activity, Dr. Starks noted 
that ACET’s formal endorsement might facilitate the development and implementation of the 
survey. 
 
ACET fully supported DTBE’s excellent proposal to develop and conduct the comprehensive 
assessment of available TB laboratory services in the United States.  Several ACET members 
made comments and suggestions for DTBE to consider in designing the survey instrument. 
 
 DTBE should design the survey to analyze and test the potential association between 
laboratory turnaround times and the likelihood that specimens would be submitted. 
 DTBE should link the comprehensive laboratory services survey instrument with RTMCC 
activities.  The RTMCCs could provide technical education and consultation to local 
laboratories in utilizing NAAT, QFT-Gold and other new technologies recommended in 
CDC guidelines. 
 DTBE should include the “incidence of laboratory contamination” as an additional topic 
to analyze in the survey. 
 DTBE should use the comprehensive laboratory services survey instrument as an 
opportunity to establish standards for the minimum number of tests laboratories should 
perform to maintain proficiency. 
 DTBE should assure anonymity to laboratories that participate in the survey.  Although 
state and local health departments would greatly benefit from having knowledge of 
specific laboratory services that are available at the local level, an anonymous survey 
most likely would yield better results.  Alternatively, the survey could be designed to 
collect and release both aggregate and laboratory-specific data. 
 
Dr. Fleenor closed the discussion by confirming that Dr. Starks’ request for ACET’s formal 
endorsement, response or recommendations on the comprehensive laboratory services survey 






Dr. Lauren Cowan is the Project Officer for the National TB Genotyping Service in DTBE.  She 
described the timeline of genotyping services offered by CDC.  In 1990, IS6110 restriction 
fragment length polymorphism analysis (RFLP) fingerprinting was introduced at CDC as a result 
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of studies that documented nosocomial and institutional transmission of TB.  In 1993, the results 
of these and other studies led to the development of recommendations for a standardized 
methodology of IS6110-RFLP and the creation of six regional fingerprinting laboratories to track 
outbreak investigations, address laboratory cross-contamination, and distinguish between re-
infection and relapse of TB cases. 
 
In 1996-2000, services provided by the six regional fingerprinting laboratories were expanded to 
include universal genotyping at seven sentinel surveillance sites by seven regional laboratories.  
Although this effort demonstrated the usefulness of universal genotyping, better and faster 
methods were still needed at the national level.  Based on this outcome, the regional 
fingerprinting laboratories were closed and CDC again was responsible for all universal 
genotyping and task order services.  CDC then developed and transferred polymerase chain 
reaction (PCR)-based methods to high throughput instruments. 
 
In 2000-2003, CDC piloted the application of the PCR-based methods and offered universal 
genotyping in six low-incidence states.  In 2004-2008, contracts were awarded to offer universal 
genotyping nationally.  A significant shift was made from IS6110-RFLP fingerprinting on all 
isolates to spoligotyping and mycobacterial interspersed repetitive unit (MIRU) typing on all 
isolates and IS6110-RFLP fingerprinting on secondary isolates.  Based on a published study, a 
proposal was made in 2007 to standardize 24-loci MIRU variable numbers of tandem repeat 
(VNTR) typing.  In 2009-2013, CDC will implement the MIRU-VNTR upgrade for universal 
genotyping. 
 
CDC contacted two laboratories in California and Michigan to provide national genotyping 
services.  During the first contract in 2004-2008, the two laboratories had the capacity to 
process 10,000 isolates per year; offered spoligotyping and 12-loci MIRU-VNTR as the primary 
typing methods; used IS6110-RFLP fingerprinting as the secondary typing method for 2,563 
isolates based on CDC’s funding capacity of 30%; and provided genotyping services at an 
average cost of $96 per isolate. 
 
In the second contract in 2009-2013, the California and Michigan laboratories will maintain the 
same capacity to process 10,000 isolates per year; offer spoligotyping and 24-loci MIRU-VNTR 
as the primary typing methods; use IS6110-RFLP fingerprinting as the secondary typing method 
based on CDC’s funding capacity of 10%; and provide genotyping services at an average cost 
of $117 per isolate.  The change in MIRU units from 12 to 24 individual loci will allow CDC to 
add and analyze more data in its national genotyping services.  However, this modification will 
not prevent CDC from consistently examining data that have been collected since 2003. 
 
CDC’s current genotyping activities are summarized as follows.  Retrospective MIRU2 typing 
will be provided for any isolate submitted for genotyping between 2003-2008 upon the request 
of TB control programs.  MIRU2 typing is being performed on 768 isolates clustered in North 
Carolina and Maryland between 2003-2006.  CDC is serving as a test site for a 24-loci MIRU kit 
to better understand the impact of the genotyping changes on TB control programs.  A proposal 









Dr. Beverly Metchock is the Team Leader of the Reference Laboratory in DTBE.  She described 
a new testing service for molecular detection of drug resistance (MDDR) that the DTBE 
Mycobacteriology Laboratory Branch (MLB) will offer later in 2009.  The goal of this service is to 
decrease turnaround times for the detection or confirmation MDR-TB and to make information 
available about second-line drug (SLD) resistance much faster than current methodologies and 
testing algorithms.  This initiative also will help MLB to generate data, inform applied research 
and facilitate the development of an improved testing service. 
 
The role of the laboratory in M.tb DST is to detect drug resistance to enable clinicians to design 
effective multi-drug regimens.  The current recommendations are to test initial M.tb isolates 
against the primary drugs of INH, rifampin (RIF), PZA and ethambutol (EMB) and to test 
secondary drugs, including fluoroquinolones (FQ), amikacin (AMK), kanamycin (KAN) and 
capreomycin (CAP), for RIF-resistant isolates. 
 
The current practice for M.tb DST includes rapid broth-based methods that are routine and 
widely available for first-line drugs.  Molecular assays for RIF and INH are available in a few 
jurisdictions and are performed on clinical specimens or culture isolates.  Very few laboratories 
have the technical expertise and capacity to test SLDs.  Testing is often performed in piecemeal 
fashion through referral algorithms and has slow turnaround times.  No consensus methods 
have been developed to date for broth-based testing of SLDs. 
 
MLB reviewed 2006 data from its M.tb DST Performance Evaluation Program to determine the 
capacity of U.S. laboratories to detect XDR-TB.  Of 104 laboratories that participated in the 
survey, 30 tested at least one SLD; nine tested all six SLD classes; and seven tested KAN, 
AMK, CAP and FQ.  The survey also showed that U.S. laboratories typically did not perform 
SLD testing as a comprehensive panel.  MLB learned that with M.tb DST, some laboratories 
were reluctant or lacked confidence in using broth-based testing to report resistance prior to 
confirmation.   
 
MLB’s new MDDR service will play an important role in three major areas.  For clinicians and 
programs, rapid confirmation of MDR-TB will be made available to jurisdictions that have an 
interest in sending isolates to the CDC laboratory.  Laboratory testing data will be made 
available to clinicians about SLD resistance in cases of RIF resistance or MDR-TB.  For 
research, services will be informed and improved by determining mechanisms of resistance, 
defining new target alleles, and confirming an association between mutation and resistance.  
For development, the correlation of molecular or genotypic results and DST or phenotypic 
results will be continuous.  New drugs and alleles will be added to the testing panel. 
 
MLB will initiate the new MDDR service with a molecular panel of nine genes and six drugs:  
RIF, INH, KAN, AMK, CAP and FQ.  Testing will be offered initially on complex isolates of M.tb 
on solid media and positive broth culture, such as MGIT.  The testing algorithm will include the 
entire molecular panel and MLB’s routine agar proportion DST panel of ten drugs and the MGIT 
system for PZA.  The method of the MDDR service will be PCR-based DNA sequencing.  MLB 
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determined that this versatile and expandable platform will generate useful information to 
facilitate interpretation of results and provide feedback on the research and development 
components of the MDDR service. 
 
Criteria for testing with the MDDR service include high-risk patients with RIF resistance or MDR-
TB from populations with high rates of drug resistance; patients exposed to MDR-TB or RF-
resistant TB cases; patients failing therapy; high-profile patients who have a significant impact 
on public health measures and patient management; patients with known RIF resistance as 
determined by first-line drug testing or the completion of molecular assays for the detection of 
RIF resistance; or patients with mixed or non-viable cultures. 
 
State public health laboratories will make test requests for the MDDR service by notifying MLB 
through a dedicated e-mail address for gate-keeping and planning purposes.  The requesting 
laboratories will be required to complete the following fields on the CDC test requisition form:  
contact information for the laboratory and individual requestor and criteria for testing. 
 
MLB will issue interim or preliminary reports with molecular results through the MDDR service 
and a final report with both molecular and agar proportion DST results.  The final report will 
include conclusions that link and explain discordance between molecular testing data and DST 
results.  The conclusions also will include data that MLB used to interpret results, such as 
predictive values of certain mutations.  Standardized language and editable boilerplate 
comments will be used for MDDR service reporting. 
 
MLB recognizes the need to provide training on the new MDDR service and is currently 
developing educational materials for laboratorians, clinicians, TB programs and RTMCCs, 
including a web site and fact sheets describing the submission protocol, clinical consultation and 
the interpretation or discordance of results.  MLB plans to evaluate the MDDR service by 
obtaining feedback from referring laboratories on the dates reported, methods and other 
aspects of their DST results as well as recommendations, problems or complaints with reporting 
language, communications or other components of the MDDR service.  MLB also intends to 
solicit input from TB programs to define the utility of the MDDR service. 
 
MLB will perform test verification of the MDDR service in two areas.  The retrospective 
evaluation will assess ~240 isolates MLB collected from 2000-2008, including MDR-TB strains 
with SLD resistance, non-MDR-TB strains with SLD resistance, isolates that are pan-susceptible 
to both first- and second-line drugs, strains from both U.S. and foreign patients, and 60 isolates 
from the 2007 and 2008 WHO Supranational Laboratory Proficiency Testing Program.  The 
retrospective verification is underway and is expected to be completed in April or May 2009. 
 
The prospective evaluation will assess ~80 isolates that state public health laboratories will 
submit to MLB in February-May 2009.  The prospective verification is underway and is expected 
to be completed in May-June 2009.  MLB will publicize the MDDR service through “Dear 
Colleague” letters disseminated by NCTA and APHL, announcements published in TB Notes, 
and a presentation during a breakout session of the National Tuberculosis Conference in the 
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MLB’s conservative estimate is that one to two requests will be made each week for the MDDR 
service.  In 2007-2008, ~134 RIF-resistant strains were referred to CDC and ~20 states refer 
M.tb cultures to CDC at this time.  The costs per isolate of CDC materials are anticipated to be 
~$50 for DST and ~$110 for the molecular panel.  In addition to the CDC costs, submitters also 
will incur costs for processing and shipping of each specimen.  Overall, MLB expects that its 
turnaround time to produce results for specimens submitted to the new MDDR service will be 
~96 hours initially if appropriate staff is available.  However, MLB will make efforts to decrease 
the turnaround time to 48 hours as the MDDR service is refined over time. 
 
Dr. Metchock concluded her overview by requesting ACET’s recognition of the new MDDR 
service as a “work-in-progress” as well as ACET’s comments and recommendations on the 
proposed plan to develop and implement the new testing service.  She pointed out that MLB 
would add new targets, refine the reporting language and improve the MDDR service as new 
information is acquired over time. 
 
Several ACET members made comments and suggestions for MLB to consider in further 
development of the new MDDR service. 
 
 MLB should offer the MDDR service for smear-positive specimens from patients who 
meet the inclusion criteria for testing.  Persons who have risk factors for drug resistance 
are the greatest challenge to clinicians and TB control programs. 
 MLB should develop a mechanism for agencies or organizations that have no 
established linkages with state public health laboratories to utilize and submit samples to 
the MDDR service.  For example, the Department of Defense (DoD) represents several 
TB laboratories, but does not routinely partner with state public health laboratories.  DoD 
has a public health issue of its overseas military and civilian populations being exposed 
to non-American patients with presumed MDR-/XDR-TB in Afghanistan.  However, 
samples that are submitted to Frankfurt, Germany are returned to DoD three to four 
months later.  MLB’s MDDR service might assist DoD in receiving diagnostic test results 
more rapidly and better protecting its overseas military and civilian populations against 
exposure to MDR-/XDR-TB. 
 MLB should design the MDDR service to analyze the association between hyper-
mutability of EMB strains that appear to predict strains and the potential of these strains 
advancing to multiple drug resistance. 
 MLB should revise the MDDR service criteria for testing to include patients who are 






Dr. Dale Stratford is the Chief of the DHAP Program Evaluation Branch.  She explained that this 
topic was placed on the agenda to address ACET’s previous concerns regarding the burden 
and amount of time grantees need to collect HIV testing data for mandatory reporting to CDC 
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and CDC’s failure to provide feedback to health department jurisdictions on the requirement for 
data reporting. 
 
CDC has collected HIV testing data since the late 1980s and published its most recent report in 
2006 with five-year HIV testing data covering 1999-2004.  CDC implemented its most recent 
reporting requirements in January 2008 with three parts on the HIV testing form.  Part 1 covers 
all HIV test events, such as test-level data.  Part 2 covers referrals for confirmed HIV-positive 
tests.  Part 3 covers jurisdictions that are funded to collect and report HIV incidence data directly 
to local HIV incidence coordinators. 
 
The HIV testing form asks grantees to respond to the following public health questions: 
 
 The number of clients who received HIV testing services by ethnicity, race, gender, age, 
risk site type and test type. 
 The number of clients who received test results by test result, client characteristics, 
including demographics and risk factors, site type and test type. 
 The proportion of total tests that are positive by client characteristics, test type and site 
type. 
 The proportion of positive tests that are newly identified based on self-reports. 
 The proportion of newly identified positive clients who developed a risk reduction plan, 
received referrals to services, and accessed those services. 
 
CDC uses HIV testing data reported by grantees to evaluate its funded HIV counseling and 
testing services based on three public health indicators:  (1) the percent of newly identified and 
confirmed HIV-positive test results among all tests reported by HIV test sites; (2) the percent of 
newly identified and confirmed HIV-positive test results returned to clients; and (3) the percent 
of facilities reporting a prevalence of HIV-positive tests equal to or greater than the jurisdiction’s 
goal.  In 2010-2015, CDC will replace public health indicator 3 with the proportion of HIV-
positive clients who were referred to medical care and attended their first appointment. 
 
CDC now requires jurisdictions to report HIV testing data 45 days after the end of each quarter, 
but grantees and DHAP have recommended semiannual reporting due to the considerable 
reporting burden.  CDC relies on feedback from the field and will analyze data to help determine 
the utility of any specific data element.  A monitoring and evaluation plan will drive future data 
needs.  Dr. Stratford presented slides of the actual HIV test form and provided an explanation 
on each of the three parts of the form. 
 
The 2005 HIV testing report is currently undergoing the CDC clearance process and will be 
released in the spring or early summer of 2009.  Analyses of 2006-2007 HIV testing data were 
initiated and are scheduled to be released in the summer of 2009.  In the future, annual national 
reporting data will be posted on the CDC web site.  Annual reports will be provided to individual 
jurisdictions and to the Division of HIV prevention and on a semiannual basis thereafter. 
 
Dr. Stratford concluded her overview by requesting ACET’s feedback or general comments on 
CDC’s HIV testing data requirements.  She emphasized that ACET’s guidance would contribute 
to refining CDC’s recommendations on program data requirements. 
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Several ACET members made comments, proposed suggestions and expressed concerns 
regarding CDC’s current reporting requirements for HIV testing.  
 
 CDC should be aware that its methodology of limiting HIV risk factors to the past 12 
months could lead to significant skewing of actual risk factors in HIV testing data 
reported by grantees. 
 CDC should seriously reconsider the implementation of a new public health indicator to 
evaluate its grantees.  Beginning in 2010, grantees will be required to report the 
proportion of HIV-positive clients who were referred to medical care and attended their 
first appointment.  However, the collection of this information from private providers will 
be extremely onerous and burdensome to local public health departments.  Because 
attendance at the first appointment for referral services is not a reportable data element, 
private providers most likely would refuse to release these data to health departments.  
 CDC should use its PCSI initiative to increase awareness in both HIV/STD and TB 
programs about TB as a risk factor for HIV, particularly in states with a low incidence of 
TB or HIV.  CDC’s education to HIV/STD and TB programs could increase the proportion 
of TB patients who are tested for HIV at the local level. 
 CDC should compile and distribute best practices to its funded programs to clearly 
distinguish between “contacts” and “investigations.”  This approach at the national level 
would better support HIV and TB prevention and control efforts in the field. 
 CDC should take extreme caution in adding more questions to the HIV test form.  The 
form is already lengthy and the addition of more questions will decrease the number of 
HIV tests performed by grantees. 
 CDC should make strong efforts to mitigate additional personnel costs and resources 
associated with grantees adhering to requirements for reporting HIV testing data.  For 
example, grantees that have made the transition to electronic medical records are 
required to complete CDC’s hard-copy HIV test form and then enter the same data into 
an electronic database.  The need for grantees to expend more personnel resources to 
comply with HIV testing data reporting requirements has resulted in CDC unintentionally 
shifting the cost of “free” HIV tests to local jurisdictions and also has led to some 
grantees opting-out of providing HIV testing in TB clinics. 
 
Ms. Suzanne Marks, a Senior Epidemiologist in DTBE, provided additional information in 
response to some of ACET’s comments.  At the division level, DTBE submitted an ESP 
proposal that requested ~$5 million in additional funding for HIV testing of TB suspects, patients 
and contacts.  At the National Center level, NCHHSTP is conducting activities at this time to 
improve sharing of HIV data among programs.  For example, NCHHSTP is currently developing 
combined guidelines for data security and confidentiality that are expected to remove barriers to 









Foreign-Born Workgroup (FBWG).  Dr. Dolly Katz, of DTBE, noted that a folder of numerous 
materials the FBWG subgroups developed to update CDC’s 1998 “Recommendations for 
Prevention and Control of Tuberculosis Among Foreign-Born Persons” was distributed to ACET 
for review and comment.  She also pointed out that the draft materials were in various stages of 
completion.  She asked ACET to be prepared to engage in a comprehensive discussion and 
provide input on FBWG’s draft foreign-born guidance document at the next meeting. 
 
Dr. Katz emphasized that FBWG’s ongoing revisions and ACET’s feedback during its next 
meeting would facilitate the completion and submission of the final draft document to the CDC 
clearance process.  She acknowledged the diligent efforts of the members of the FBWG and its 
subgroups in drafting and extensively revising the foreign-born guidance document over the 
past five years. 
 
Stop TB in the African American Community Workgroup.  Ms. Gail Burns-Grant is a TB 
Program Consultant in DTBE.  She reported that the workgroup agreed to focus on three target 
areas:  research, protocols and guidelines, and community awareness and outreach.  TBESC’s 
Task Order 11 intervention of “Working Together to Stop TB: Building Community Partnerships 
to Eliminate TB in African American Communities” supports the workgroup’s three focus areas 
and was designed to overcome treatment barriers to TB disease and LTBI and. 
 
Findings from the Task Order 11 intervention demonstrated inconsistent messages about TB in 
the AA community; the need for a stronger partnership between public health and the 
community to address TB; and the need for guidance and concrete action steps to establish and 
improve practices.  To advance the Task Order 11 intervention, formative activities were 
conducted with health departments and communities.  DTBE provided funding and technical 
assistance.  The Southeastern National Tuberculosis Center (SNTC) and the Research Triangle 
Institute collaborated to develop a toolkit that is scheduled to be distributed in May 2009. 
 
The toolkit includes a number of resources to facilitate closer collaboration among CDC partners 
and communities, such as a DVD, user’s guide with tools, invitation letter and meeting agenda 
with the campaign logo, PowerPoint presentations, facilitator’s guide, and links to resources on 
the SNTC web site.  Health departments and their external partners are the target audiences for 
the DVD.  The DVD will be available on the Internet and in hard copy upon request, but CDC 
and its partners are currently developing a more formal and broader dissemination plan.   
 
DTBE conducted a number of activities to support the “Working Together to Stop TB” 
intervention.  Fact sheets on TB in AAs and other minority groups were updated with the most 
recent surveillance data and posted on the CDC web site for access by partners.  The TB in AA 
web page is being redesigned to match CDC’s web templates and to be user-friendlier.  DTBE’s 
multidisciplinary Health Disparities Workgroup (HDW) is continuing to extensively collaborate 
with partners.  A number of ESP and DTBE lead proposals were developed and submitted to 
compete for FY2009 funding. 
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HDW participated in or presented at several events, including a HRSA meeting, NCHHSTP’s 
SDH Consultation and health disparity lectures, Gay Pride activities, DTBE brown bag lunches, 
the TB program manager’s course, Task Order 23 Workgroup, and Health Disparity Workgroups 
for both CCID and NCHHSTP.  HDW also nominated external participants to attend NCHHSTP 
meetings.  Ms. Burns-Grant concluded her overview by showing the “Working Together to Stop 
TB” DVD. 
 
ACET commended CDC and its partners on producing the outstanding “Working Together to 
Stop TB” toolkit, particularly the excellent DVD.  Several ACET members made comments and 
suggestions for CDC and its partners to consider in broadly disseminating the toolkit. 
 
 CDC and its partners should utilize diverse and innovative venues to widely disseminate 
the toolkit and reach more audiences.  Distribution methods that should be considered 
for the toolkit include the National Medical Association (NMA) and other provider 
organizations; the National Association of Community Health Centers and other health 
center advocacy groups that are funded by or collaborate with HRSA; the African 
American Workgroup; Task Order 23 Community Advisory Boards; HRSA’s Knowledge 
Management System Virtual Office; and RTMCC breakout sessions, poster sessions or 
newsletters featured during National TB Controllers meetings. 
 CDC and its partners should submit the DVD to the National Association of County and 
City Health Officials to compete for the “Model Practice Awards.”  This approach could 
be used to promote and broadly distribute the DVD as an innovative social marketing 
product. 
 CDC and its partners should use non-governmental organizations and other creative 
mechanisms to present the DVD to subpopulations in the AA community with the highest 
risk for TB. 
 CDC and its partners should launch and target a national educational campaign to 
audiences that will use the toolkit.  This strategy will increase the effectiveness and 
actual implementation of the toolkit.  Moreover, solid partnerships will be extremely 
important to strengthen knowledge and understanding of cultural differences regarding 
TB in the AA community.  At the local level, for example, health departments could 
collaborate with churches, beauty salons, barbershops and other community partners to 
provide education on TB in the AA population.  To seriously address this issue, local 
health departments must make a strong commitment to provide leadership to and 
collaborate with communities.  At the national level, NMA could serve as a solid partner 
in providing education on TB to AA physicians due to its location in six regions that cover 
the entire country. 
 
Ms. Marks informed ACET that two papers were recently published addressing substance 
abuse among TB patients and knowledge, attitudes and perceptions regarding TB disparities in 
certain populations. 
 
Joint BCG Workgroup with the Advisory Committee on Immunization Practices (ACIP).  
Dr. Elsa Villarino, of DTBE, reported that the 1996 ACET/ACIP document recommended the 
use of BCG for the prevention of TB among HCP in the United States in three situations:  (1) a 
high percentage of TB patients infected with MDR-TB; (2) transmission of drug-resistant TB to 
 
 
ACET Meeting Minutes                                  March 3-4, 2009                                                         Page 28 
HCP and the likelihood of subsequent infection; and (3) implementation of infection control 
measures with no demonstrated success in preventing transmission.  The 1996 ACET/ACIP 
guidance document also recommended the use of BCG for prevention of TB in children who 
were continuously exposed to MDR-TB. 
 
The 1996 ACET/ACIP BCG recommendations were rarely implemented because the efficacy of 
the vaccine was found to be highly variable.  Two large and comprehensive meta-analyses 
showed that the efficacy of BCG ranged from 0%-80% and the capacity of the vaccine to 
prevent disease in adults was questionable.  Other studies demonstrated that BCG interfered 
with the interpretation of TST; experience with BCG was limited in the United States; the 
vaccine was not readily available; and infection control measures were effective. 
 
ACET considered the need to extensively review the 1996 BCG vaccine guidelines due to a 
number of factors.  TB epidemiology changed globally; the incidence of MDR-TB increased; and 
XDR-TB became an emerging problem.  HCP, volunteers and students continued to conduct 
activities with high-risk populations through humanitarian efforts and university research 
programs.  Implementation of infection control measures was found to be inadequate or 
incomplete.  Transmission of TB in healthcare facilities was shown to affect HCP and patients 
and also amplify HIV.  The availability of IGRA as a diagnostic tool for LTBI eliminated concerns 
regarding false-positive TST results due to BCG. 
 
Based on these factors, ACET formed a new BCG Workgroup in 2008 with the following charge.  
New literature related to the efficacy of BCG would be reviewed.  Recommendations would be 
offered for HCP, volunteers and students who travel to work in areas of the world where the 
incidence of MDR-/XDR-TB is high and infection control measures are inadequate.  A joint 
writing committee would be formed with ACIP to ensure that the updated BCG guidelines would 
have the same co-endorsement as prior versions.  ACET recognized that the workgroup’s 
recommendations would be “expert opinion” for the most part. 
 
The workgroup’s charge was modified in 2009 as follows.  The scope of the guidance document 
would be expanded from a targeted update of the 1996 BCG recommendations.  The target 
audience of the recommendations would be HCP providing care to persons who travel for work 
in areas with a high risk for M.tb transmission.  ACIP no longer would serve as a joint author of 
the guidance document.  A new title was proposed to reflect the scope of the new guidelines:  
TB Prevention and Control Measures for U.S. Healthcare Workers and Volunteers Serving in 
High-Risk Settings for Exposure to M. tuberculosis. 
 
The guidance document developed under the modified charge would propose BCG vaccination 
as only one of several potential interventions with the following recommendations.  BCG 
vaccination should be administered at least eight weeks prior to travel when possible.  The 
workgroup agreed on eight to ten weeks as an appropriate time frame for travelers to develop 
an immune response following TB exposure.  This time frame also would allow an evaluation of 
immune response by IGRA or TST prior to the traveler’s departure.  The evaluation should be 
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The post-travel evaluation should be conducted two months after exposure ends.  The medical 
assessment to detect signs and symptoms of TB should be performed by IGRA and TST.  If the 
medical assessment shows evidence of LTBI or symptoms, a chest x-ray should be performed 
and a referral should be made to local experts, state TB consultants, RTMCCs or another expert 
in the treatment of MDR-TB. 
 
The workgroup convened a conference call in February 2009 to review the current draft 
guidance document and highlight areas that were absent or under-represented.  After all 
pertinent sections of the guidance document are clearly defined, a new outline will be developed 
and writing tasks will be assigned to each workgroup member.  A timeline will be created for the 
workgroup to produce the revised guidance document.  Input provided by ACET during the 
March 2009 meeting will be considered. 
 
Dr. Edward Nardell, ACET’s liaison to IUATLD, added that the guidelines also would emphasize 
the need to develop a better respirator for HCP and volunteers to use in low-income countries. 
 
ACET was divided on whether additional efforts should be made to further develop and release 
the guidance document with a modified scope.  On the one hand, several members noted that 
the 1996 BCG guidelines need to be updated and expanded at this time.  The members 
emphasized the need for CDC to provide advice to persons who work in areas of the world with 
extremely high-risk populations and inadequate infection control measures.  The members also 
pointed out that the safety and efficacy of BCG are well known and the vaccine most likely is 
safer than a rifampin/moxifloxacin regimen. 
 
The members clarified that ACET’s guidance document would recommend BCG vaccination as 
only one of several potential interventions for persons who travel to high-risk areas for MDR-TB.  
The guidance document also would strongly emphasize the need for persons to be evaluated 
and educated pre-/post-travel.  The members suggested that at some point after the release 
and implementation of ACET’s guidance document, data on the effects and outcomes of BCG 
vaccination could be collected and rigorously assessed. 
 
On the other hand, a number of ACET members expressed serious concerns with the guidance 
document in three major areas.  First, ACET would develop and release CDC recommendations 
with no evidence basis.  Knowledge is lacking on the use of BCG in high-risk settings and the 
immunology of administering the vaccine to adults.  Moreover, no data have been collected to 
date to assist providers in caring for patients who have a positive IGRA or TST result after 
exposure to MDR-/XDR-TB. 
 
Second, ACIP is no longer a joint author on the updated guidance document.  Because the joint 
1996 ACET/ACIP BCG recommendations are posted on the CDC/ACIP web site, ACET’s 
updated document might conflict with the previous guidance and cause confusion.  However, 
this problem could be avoided if the availability of the 1996 BCG recommendations is noted in 
ACET’s updated guidance document.  Third, BCG potentially could be viewed as a “traveler’s 
vaccine” on CDC’s web pages for international travelers.  As a result, the actual protection and 




ACET Meeting Minutes                                  March 3-4, 2009                                                         Page 30 
Several ACET members made specific comments and suggestions on the modified scope of the 
guidance document.  
 
 The proposed title of the guidance document should be shortened, but exposure to both 
M.tb and MDR-TB should be emphasized in the title. 
 The focus of the guidance document should not be limited to HCP in high-risk settings.  
The recommendations also should be targeted to other populations at high risk in 
developing countries, such as persons who work in refugee centers, homeless shelters, 
prisons and other high-incidence areas. 
 The potential side effects of BCG in adults should be carefully considered before issuing 
guidance on the vaccine.  The literature shows that BCG is toxic and can cause 
disfiguring scars or draining sinuses.  The guidelines should provide a stronger directive 
or instructions on the use of BCG, particularly for providers with no experience or 
knowledge in administering the vaccine. 
 Challenges with some of the interventions proposed in the guidance document should 
be addressed.  For example, the value of pre-/post-testing of IGRA has not been 
validated to date.  Exposure to MDR-TB is the primary concern in high-risk settings, but 
the majority of local populations in these areas would be sensitive to TB.  As a result, the 
guidance document should not necessarily recommend a rifampin/moxifloxacin regimen 
at the outset because INH would still be an option. 
 ACET should develop and release a formal statement calling for a significant U.S. 
initiative to help define better methods for infection control in developing countries. 
 
Dr. Fleenor confirmed that during the business session on the following day, the workgroup’s 
request for ACET to formally endorse the proposed changes to its charge would be discussed.  
The outcome of ACET’s vote on this issue would determine whether additional efforts would be 
made to further develop and release the updated guidance document with a modified scope. 
 
With no further discussion or business brought before ACET, Dr. Fleenor recessed the meeting 






Dr. Fleenor reconvened the ACET meeting at 8:30 a.m. on March 4, 2009 and yielded the floor 
to the first presenter. 
 
Dr. Mark Lobato, of DTBE, described the New England TB Consortium’s (NETC) regionalization 
strategy for TB control and elimination.  Because regionalization has advanced from a concept 
to reality over time, lessons learned should now be translated into generalized practice.  
Regionalization relates to field-based interventions by providing a rapid response to problems, 
increasing program capacity, promoting cooperation between federal and state agencies, 
strengthening program effectiveness, and reflecting a changing relationship between DTBE and 
states. 
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Regionalization is currently meeting the challenge of a number of issues, such as flat funding, a 
weakened public health infrastructure, loss of TB expertise, ongoing immigration that is leading 
to a global epidemic with implications for the United States, continued outbreaks in vulnerable 
populations, and minimal new diagnostics and drugs.  Of the six states in the New England 
region, four are considered to be low-incidence areas.  However, aggregated case rates in the 
region would be equivalent to the eighth highest TB burden in the United States.  Moreover, TB 
is concentrated in several urban areas in the region with case rates >10-12/100,000. 
 
The purpose of initiating the regionalization strategy in the New England region was to invest in 
core TB program activities.  The six participating states designed the NETC collaboration for 
change in TB control with six key components:  leadership, education, communication, 
genotyping, public health law and awards.  Additional details on the NETC components are 
described below. 
 
“Eliminating TB Case-by-Case” is a case series for providers and clinicians.  An interactive web-
based presentation with CDC continuing education credits was made in June 2008 to 
strengthen knowledge among providers in using QFT-Gold for TB testing.  The case series are 
presented by master clinicians to reach private providers and strengthen the TB network in the 
New England region.  “TB Talk-New England” is a case discussion by and for nurses, outreach 
educators and case management staff.  Three case discussions have been held to date and the 
January 2009 “Ask the Expert” presentation featured a panel of TB experts with specialties in 
pulmonary, infectious disease and pediatric medicine. 
 
The NETC web site at www.newenglandtb.org is currently being redesigned and serves as a 
mechanism to increase cohesiveness and visibility, promote regional and state education, and 
exchange tools and materials internally among programs and externally among providers and 
other groups.  NETC’s Genotyping Workgroup defined data management capacity, identified 
instances of interstate transmission in two clusters, highlighted missed opportunities, and 
measured strain dispersion across states. 
 
NETC’s consultation component provided early detection of outbreaks, emphasized the need for 
a CDC investigative team, facilitated technical support for three large contact investigations, and 
performed an average of seven consultations for contact investigations and 20 consultations for 
complex cases each year.  NETC’s Public Health Law Project was based on a call to action that 
was unanimously passed during the Northeast TB Meeting and forwarded to NTCA.  The project 
addressed gaps in the Model TB Act, formed a broad partnership, and defined options for 
involuntary isolation of patients from other states.  The project was submitted for consideration 
of CDC’s “Innovations in Public Health Policy Award.” 
 
The “1st Annual New England TB Heroes Award” was presented at the 2008 Northeast TB 
meeting to energize programs, strengthen the focus on TB, and acknowledge exceptional 
contributions to TB control and the well-being of patients and communities.  The award is 
featured in the current edition of TB Notes.  A call for nominations for the “2nd Annual New 
England TB Heroes Award” was recently released.  NETC is continuing its focus on PCSI to 
enhance collaborations between TB and other health department programs, particularly HIV and 
STD programs.  NETC’s PCSI activities were highlighted in a 2008 TB Notes article. 
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Laboratory collaborations are not a formal part of NETC, but are considered to be an essential 
component.  At this time, five of six states in the New England region are administering a 
uniform survey to obtain data on current laboratory practices and capacity for TB diagnostics in 
hospitals and commercial laboratories.  The survey also could serve as a marketing tool to 
encourage hospitals to utilize state laboratories. 
 
NETC has widely publicized its activities and lessons learned since 2005 in a variety of venues, 
such as events sponsored by NTCA, ATS, IUATLD and TBETN; Northeast TB Conferences; 
and DTBE brown bag lunches.  NETC also produced publications on TB in FBP, TB outbreaks 
in a community and a Connecticut prison, TB heroes, PCSI, TB regionalization and education. 
 
DTBE evaluated NETC in the spring of 2008 to determine the factors that promote or hinder 
regionalization efforts.  The evaluation showed that NETC created a formal framework with a 
consensus plan of action; provided a structure for all voices to be equally heard; and facilitated 
the sharing of knowledge and resources.  The evaluation also demonstrated NETC’s resource 
limitations that hinder program staff from optimizing involvement. 
 
The evaluation concluded that NETC provides a model for building consensus through strategic 
planning and establishing formal agreements.  Regional assignees were found to be effective in 
promoting regionalization and providing skills and resources as incentives to promote 
collaborative efforts.  The full evaluation report of NETC was distributed to ACET for review. 
 
Overall, the NETC regionalization project showed that modern TB control requires team 
leadership and trans-jurisdictional coordination and collaboration of activities.  The project also 
demonstrated that regional efforts enhance individual programs and offers several advantages 
to CDC.  To advance NETC, a leadership retreat will be held in the next few months to improve 
collaborative efforts, update the strategic plan and analyze strategies to replicate the model.  
Additional efforts will be made in the future to formally expand the NETC model to laboratories 
and refugee coordinators and enhance resources for treating complex or non-adherent patients.  
The long-term goal will be to extend the NETC model nationally and strategically place TB staff. 
 
Dr. Lobato concluded his overview by asking ACET to provide input on two key issues.  First, 
what approaches should NETC implement to increase support to state programs?  Second, 
what aspects of NETC should be enhanced? 
 
The ACET members made a number of comments and suggestions in response to Dr. Lobato’s 
request for input on the NETC regionalization model. 
 
 Advocacy should be added as another key component of the NETC regionalization 
model to increase involvement by health departments in TB control and elimination 
efforts and ensure that smaller TB programs remain functional. 
 A formal retrospective evaluation should be conducted of HHS’s previous regionalization 
model to determine successes and lessons learned that could be applied to strengthen 
the NETC regionalization project. 
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 A formal prospective evaluation should be conducted to analyze differences between the 
success of the NETC regionalization model in the New England region versus the 
potential lack of success of the project in other areas of the country.  This assessment 
should be performed before efforts are made to expand the NETC regionalization model 
nationally. 
 Lessons learned from the NETC regionalization model should be strongly linked and 
applied to the future structure of DTBE’s TB cooperative agreement and TB funding 
formula. 
 Stronger emphasis should be placed on the role of RTMCCs in the NETC regionalization 
model.  The capacity of RTMCCs to provide TB training and medical consultation in four 
regions in the country is extremely important to and meets the needs of the New 
England region. 
 
Dr. Fleenor announced that the ACET meeting would be adjourned at a much earlier time than 
noted on the published agenda.  The acting Director of CDC approved a directive from the 
Office of Health and Safety for all occupants of CDC’s Corporate Square Offices to evacuate the 
building due to a water main break. 
 
As a result of this unexpected development, Dr. Fleenor explained that the remaining updates 
on the published agenda either would be truncated or tabled until the next meeting.  He also 
pointed out that ACET would only discuss and attempt to resolve its most pressing issues 







Dr. Richard Goodman, of the CDC Public Health Law Program, reported on CDC’s progress on 
this initiative since the October 2008 ACET meeting.  The Practitioner’s Handbook on TB 
Control Law, its companion PowerPoint slides for instructional purposes, and the scenario for 
assessing the sufficiency and understanding of TB control law in jurisdictions were completed 
and are now ready for dissemination. 
 
The first draft of the TB Control Model Act was widely distributed in November 2008 to a large 
number of organizations and individuals.  In January 2009, CDC compiled all feedback that was 
submitted on the model act.  The input broadly ranged from immediate endorsement, insightful 
comments on the need for significant revisions and sharp criticism. 
 
Most notably, three organizations requested face-to-face meetings with the authors of the model 
act to amplify their concerns regarding the strong emphasis on the ethics of voluntarism; heavy 
reliance on “non-essential” components of the Turning Point Model State Public Health Act; and 
the need to capture more best practices from CDC’s study of expressed TB control laws in 25 
jurisdictions in the model act. 
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The meeting between the three organizations and the authors of the model act would be held on 
the following day.  Dr. Narita would attend the meeting to represent ACET.  The overarching 
purpose of the meeting would be for the organizations to present principal thematic areas of 
concern and for the authors to outline a clear plan to respond to the organizations’ concerns.  
The authors also would assure the organizations that changes would be made to maximize the 
use of the model act by organizational members, constituents and stakeholders. 
 
Dr. Goodman concluded his update by asking ACET to formally endorse the completed 
handbook, companion PowerPoint slides and scenario at this time; formally endorse the model 
act during the July 2009 meeting; and formally recommend the use of the model act only in 
situations where the scenario has been implemented to convene key officials, assess the status 






Drs. Gary Simpson, of the State of New Mexico Department of Health (retired) and Damian 
Gessler, of the New Mexico National Center for Genome Resources, explained that TB is now 
more complex and drug-resistant, develops faster and originates in other parts of the world.  
However, 19th century strategies are still being applied at this time to eliminate the disease.  To 
address this gap, a multidisciplinary workgroup was established to identify necessary tools to 
eliminate TB in the 21st century. 
 
TB is now at the edge of a paradigm changing approach for infectious diseases due to its high 
degree of international relevance, ability to be managed in the United States and 100-year 
infrastructure.  A 20-billion genome basis on human data in a single run was achieved in 
February 2009 at a cost of ~$30,000-$50,000.  This technology has the capacity to combine 
strains and genomes in a 4.4-megabyte TB genome with a 95-gigabyte run to sequence ~1,100 
genomes in three to seven days.  The cost per genome would be ~$10 or ~$120,000 to 
sequence every new case of TB by 2010.  Technological changes in full genome sequencing 
are completely revolutionizing science at this time. 
 
Sequencing deliverables include the detection of single nucleotide and insertion/deletion 
polymorphisms; high-resolution molecular epidemiology; population-based phylogenomics; and 
epistatic or full genome contributions to traits of public health significance, such as virulence, 
transmissibility, MDR-/XDR-TB, environmental and social risk factors, and population-based 
surveillance. 
 
Evidence-based decision-making needs to be targeted to TB at the national level due to the low 
incidence, strong threat and high visibility of the disease.  Public health professionals, clinical 
decision-makers and scientific researchers should have timely access to aggregated and 
integrated information on TB.  In 2006, a policy science paper was published that introduced the 
concept of a National TB Archive (NTBA) based on consensus and endorsement by >24 of the 
country’s most highly regarded experts in the fields of science, medicine and public health. 
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The NTBA would be the first comprehensive and integrated information and biological resource 
developed for a human pathogen in the United States.  Existing investments that have been 
made in RVCT and the Universal Genotyping Program would be utilized to collect isolates from 
every TB case in the United States. 
 
Etiological agents would be archived in the NTBA along with certain full genome sequencing 
and phylogenetic components.  Although the NTBA would be accessible on the Internet, only 
credentialed persons would be allowed access to integrated genomic, phylogenetic, clinical or 
epidemiological data.  Moreover, researchers could use the NTBA to conduct trace-backs from 
informatic searches to archived isolates and close the loop between etiological agents and 
evidence-based decision-making. 
 
The immediate benefits of the NTBA would include a national and visionary scope, assistance 
to local and trans-jurisdictional contact investigations, identification of molecular-based cryptic 
MDR-/XDR-TB threats, and the ability to prospectively allocate resources and conduct planning.  
The NTBA also is relevant to the 2009 ESP due to its ability to increase local efficiencies 
through national capabilities; facilitate multi-state collaborations; add value to existing 
investments in universal genotyping; provide a 21st century approach to a global problem that is 
not retreating; and advance the baseline etiologic and informatic infrastructure in preparation of 
future technologies and challenges. 
 
The NTBA would not change data release policies or data security levels.  Private data would 
remain private and public information would remain public.  For example, credentialed persons 
at the local level would be given access to county-level data for health departments and other 
local information.  Persons with credentials for shared data would be given access to authorized 
trans-jurisdictional information.  The public would be given access to aggregate reports and 
other public data.  The NTBA would increase the efficiency of data access and analysis for 
existing credentialed persons, produce evidence-based, real-time and actionable information, 
and generate new discoveries. 
 
The NTBA would be designed with architectural and technological principles to safeguard 
patient confidentiality.  Data would be pathogen-centric rather than patient-centric.  Names, 
addresses and other identifying data from RVCT would not be stored in or accessible via the 
NTBA.  The NTBA would be developed with a dual-accession numbering system in which RVCT 
numbers would be stored at state health departments and linked to a hidden record number and 
public isolate accession number. 
 
Overall, existing assets would be compiled and brought to bear to change the current approach 
to addressing TB.  TB would be modeled as a national infectious disease response.  Drs. 
Simpson and Gessler concluded their overview by requesting ACET’s input and endorsement 









ISSUE 1:  The following motion was properly placed on the floor and seconded by Drs. Burman 
and Seaworth, respectively: 
 
 WHEREAS, HIV testing of persons with TB and their close contacts is an 
identified public health priority; 
 
 WHEREAS, the reporting requirements for CDC-sponsored HIV testing programs 
are time-consuming and are a deterrent to comprehensive TB testing in TB 
control programs; 
 
 WHEREAS, the recently adopted reduced reporting requirements for HIV testing 
programs are an improvement, but these testing requirements continue to be a 
barrier to more wide-scale HIV testing in TB control programs; 
 
 WHEREAS, data on newly diagnosed cases of HIV infection are an important 
part of HIV surveillance and control efforts, but information on all persons who 
are tested is of much less importance and cannot be derived from CDC-
sponsored testing programs.  A number of large HIV testing programs do not 
report to CDC; and 
 
 BE IT RESOLVED that CDC should reevaluate the reporting requirements for 
CDC-sponsored HIV testing.  These reporting requirements should focus on 
persons found to be HIV-infected and collect little if any information on persons 
found to be HIV-negative. 
 
ACET unanimously approved the motion with no further discussion. 
 
ISSUE 2:  The following motion was properly placed on the floor and seconded by Mr. Kinney 
and Dr. Narita, respectively:  “ACET endorses or otherwise communicates its approval of using 
the completed TB control law resources, i.e., the handbook and companion PowerPoint slides, 
scenarios and report on expressed TB control laws.”  ACET unanimously approved the motion 
with no further discussion. 
 
ISSUE 3:  The following motion was properly placed on the floor and seconded by Drs. Seaworth 
and Burman, respectively:  “BE IT RESOLVED that ACET commends and supports CDC’s 
proposed additional service of offering molecular detection of drug resistance testing.”  ACET 
unanimously approved the motion with no further discussion. 
 
ISSUE 4:  The following motion was properly placed on the floor and seconded by Drs. Seaworth 
and Bakhtawar, respectively:  “BE IT RESOLVED that ACET recognizes the need for and 
recommends a comprehensive assessment of all public and private domestic laboratory 
services.”  ACET unanimously approved the motion with no further discussion. 
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ISSUE 5:  The following motion was properly placed on the floor and seconded by Drs. Seaworth 
and Burman, respectively: 
 
WHEREAS, ACET recognizes the potential for exposure to MDR-/XDR-TB of 
U.S. travelers who provide medical care or humanitarian volunteer services to 
persons with these diseases in situations where infection control practices are 
inadequate or lacking, the risk for transmission and infection are possible, and no 
treatment for LTBI in these persons has been shown to be effective; and 
 
BE IT RESOLVED that ACET recommends the established workgroup change its 
objective from a focus on the use of BCG to more general recommendations on 
approaches to protect humanitarian and scientific travelers from the United 
States to endemic areas of MDR-TB where exposure and infection are possible. 
 
ACET unanimously approved the motion with no further discussion. 
 
ISSUE 6:  A motion was properly placed on the floor and seconded by Drs. Seaworth and Lopez-
de Fede, respectively, for ACET to accept the previous minutes.  ACET unanimously 
approved the October 7-8, 2008 Draft Meeting Minutes with no further discussion. 
 
ISSUE 7:  Dr. Fleenor led ACET in a review of the action item and future agenda items that were 
raised over the course of the meeting. 
 
 Action Item 
 Ms. Margie Scott-Cseh, the ACET Committee Management Specialist, will distribute an 
electronic version of FBWG’s documents to ACET. 
 
Future Agenda Items 
 Overview of NTIP with regular updates as the initiative is rolled out. 
 Update on the TBESC evaluation of immunogenetic and immunologic markers for 
susceptibility to M.tb and progression to TB disease. 
 Regular updates on the SDH initiative. 
 ACET discussion and formal endorsement of the TB Control Model Act [July 2009 
meeting]. 
 ACET discussion and formal endorsement of the NTBA [July 2009 meeting]. 






Dr. Fleenor opened the floor for public comments; no participants responded. 
 









The next ACET meeting would be held on July 14-15, 2009.  With no further discussion or 
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